Cytheris and Cancer Immunotherapy Trials Network (CITN) announce selection of recombinant interleukin-7 (CYT107) for initial studies at member institutions
18-May-2011 -
Cytheris SA and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC), announced the selection of recombinant human interleukin-7 (CYT107), the investigational ...
cancer
immunotherapies